MET and gastric cancer: Savolitinib is a selective c-MET tyrosine kinase inhibitor that was granted approval in China for the treatment of metastatic NSCLC with MET exon 14-skipping alterations.600 In the VIKTORY umbrella trial, patients with metastatic GC were assigned to eight different biomarker groups to receive corresponding targeted drugs as second-line treatment.601 Savolitinib was assigned to treat patients with MET amplification.